

14th Immunisation Seminar



Thursday 23rd March 2017 Richard Doll Building, Old Road Campus, Roosevelt Drive, Headington, Oxford OX3 7LF

Time	Topic	Speaker
08.30 - 09.10	Coffee & registration	
09.10 – 09.15	Welcome from the Chair	Karen Ford, Immunisation Nurse Specialist, OVG
09.15 - 09.45	Research activities at OVG in 2016 and beyond	Prof Andrew J Pollard Professor of Paediatric Infection and Immunity, OVG
09.45 – 10.30	Contemporary achievements of the UK immunisation programmes and possible upcoming changes	Joanne Yarwood National Immunisation Programme Manager Public Health England
10.30 – 11.00	Immunisation coverage in Thames Valley – tackling local variations	Paula Jackson and Nisha Jayatilleke Consultants in Public Health Thames Valley Screening and Immunisation Team NHS England
11.00 – 11.30	Coffee	
11.30- 12.00	Initial efficacy data of the Men B infant vaccination programme	Dr Shamez Ladhani PID Consultant at St. George's Hospital, Senior Lecturer at St. George's University of London and Consultant Epidemiologist at Public Health England
12.00 – 12:15	A survey of infants presenting with fever following Men B vaccination to A&E at the Children's Hospital, Oxford	Dr Matthew Snape Consultant in Vaccinology and General Paediatrics, OVG and Oxford University Hospitals NHS Trust
12:15 -12:35	Aiming higher and improving Men B vaccine: Better understanding of immune responses to Men B vaccination in adults and other developmental work	Dr Christine Rollier Senior Post Doctoral Researcher, OVG
12:35-13:15	Debate: "Should Men ACWY be included in the infant schedule in response to the current increase in cases of Men W?"	Prof Andrew J Pollard (Chair) Dr Shamez Ladhani Dr Matthew Snape
13:15 – 14.15	Lunch	
14.15 – 15.00	Ask the panel	Prof Andrew J Pollard (Chair), Dr Matthew Snape, Dr Dominic Kelly, Joanne Yarwood, Dr Shamez Ladhani
15.00 – 15:25	Pertussis: Update and future approaches	Dr Dominic Kelly, Consultant in Vaccinology, Oxford University Hospitals NHS Trust and OVG
15:25 - 15.55	Why Live Attenuated Influenza Vaccine should continue to be used for the childhood programme	Prof Andrew J Pollard Professor of Paediatric Infection and Immunity, OVG
15.55	Closing Remarks	